Cargando…
Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study
BACKGROUND: Some patients with advanced or recurrent, epidermal growth factor receptor (EGFR) mutation-positive (EGFR M+) non-small-cell lung cancer (NSCLC) continue to receive EGFR tyrosine kinase inhibitors (TKIs) beyond radiological progression. METHODS: We analysed a cohort of 577 patients with...
Autores principales: | Goto, Yasushi, Tanai, Chiharu, Yoh, Kiyotaka, Hosomi, Yukio, Sakai, Hiroshi, Kato, Terufumi, Kaburagi, Takayuki, Nishio, Makoto, Kim, Young Hak, Inoue, Akira, Hasegawa, Yoshinori, Isobe, Hiroshi, Tomizawa, Yoshio, Mori, Yoshiaki, Minato, Koichi, Yamada, Kazuhiko, Ohashi, Yasuo, Kunitoh, Hideo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604715/ https://www.ncbi.nlm.nih.gov/pubmed/29018574 http://dx.doi.org/10.1136/esmoopen-2017-000214 |
Ejemplares similares
-
Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)
por: Naka, Go, et al.
Publicado: (2022) -
Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2022) -
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021) -
Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study
por: Watanabe, Kageaki, et al.
Publicado: (2022) -
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)